We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Jagged Ends of Double-Stranded DNA Characterized

By LabMedica International staff writers
Posted on 10 Sep 2020
Cell-free DNA in plasma has been used for noninvasive prenatal testing and cancer liquid biopsy. More...
The physical properties of cell-free DNA fragments in plasma, such as fragment sizes and ends, have attracted considerable recent interest.

This awareness has led to the emerging field of cell-free DNA fragmentomics. However, one aspect of plasma DNA fragmentomics as to whether double-stranded plasma molecules might carry single-stranded ends, termed a jagged end, remains underexplored.

A group of scientists at the Chinese University of Hong Kong (Shatin, Hong Kong SAR, China) and their associates collected blood samples from a cohort 30 pregnant women, as well as from another cohort that included 34 hepatocellular carcinoma (HCC) patients, eight healthy controls, and 17 chronic hepatitis B virus patients. After amplifying and extracting plasma from the samples, the team performed a jagged end by sequencing analysis (Jag-seq) on the two cohorts. The team developed two variants of Jag-seq to investigate the presence of jagged ends in a plasma DNA pool. Jag-seq applies DNA end repair to introduce differential methylation signals between the original sequence and the jagged ends, depending on whether unmethylated or methylated cytosines were used in the DNA end-repair process.

In the first cohort, the scientists used Jag-seq (methylated) to look for differences in jaggedness between maternal and fetal cfDNA in the pregnant women. They saw that the average jagged end length of fetal DNA molecules was higher than that of the maternal counterparts and that fetal DNA was more jagged overall. In the second cohort, they applied Jag-seq (unmethylated) to the HCC blood samples, finding that tumor-derived DNA molecules showed an increased jaggedness compared to non-tumor DNA. While the approach had an area under the operating curve of 0.87, they noted that the method would likely be used in combination with other approaches to aim for even higher sensitivity and specificity. In addition, the team saw that jaggedness varied depending on plasma DNA fragment sizes and appeared to be linked to nucelosomal patterns.

The authors concluded that in the plasma of pregnant women, the jaggedness of fetal DNA molecules was higher than that of the maternal counterparts. The jaggedness of plasma DNA correlated with the fetal DNA fraction. Similarly, in the plasma of cancer patients, tumor-derived DNA molecules in patients with hepatocellular carcinoma showed an elevated jaggedness compared with non-tumoral DNA. The study was published on August 14, 2020 in the journal Genome Research.

Related Links:
Chinese University of Hong Kong


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.